Clinical Trials Directory

Trials / Completed

CompletedNCT06483750

Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction

The Efficacy of the Systane iLux System on Preoperative Cataract Patients on Dry Eye Disease Due to Meibomian Gland Dysfunction

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
George Washington University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This prospective study will investigate the effect of pre-operative Systane iLux system administration in treated cataract induced dry eye disease.

Detailed description

Eligible patients to be recruited will have scheduled upcoming senile cataract surgery. Enrolled patients in the active arm (n=25) will receive pre-operative Systane iLux treatment two weeks prior to surgery at the baseline visit. Patients in the control arm will receive no Systane iLux treatment at the baseline visit two weeks prior to cataract surgery. Patients will be assessed on baseline metrics for dry eye disease stemming and meibomian gland dysfunction (MGD) at the baseline visit two weeks prior to cataract surgery. These metrics include tear break up time (TBUT), standard patient evaluation of eye dryness questionnaire (SPEED), ocular surface and surface disease index (OSDI) surveys, and lipid layer thickness (LLT). At the follow up visit four weeks after cataract surgery, these same metrics will be assessed again for any significant changes.

Conditions

Interventions

TypeNameDescription
DEVICESystane iLux TreatmentThe Systane iLux is an approved thermal pulsation device to treat dry eye disease. The application of heat and compression to both eyelids melts meibum in the obstructed glands to restore the secretion and production of meibum to the eye. The Systane iLux will only be administered to the eye to undergo cataract surgery.

Timeline

Start date
2024-06-03
Primary completion
2025-02-01
Completion
2025-02-01
First posted
2024-07-03
Last updated
2026-02-05

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06483750. Inclusion in this directory is not an endorsement.